Insulin detemir
- Generic Name
- Insulin detemir
- Brand Names
- Levemir
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 169148-63-4
- Unique Ingredient Identifier
- 4FT78T86XV
- Background
Insulin detemir is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin ...
- Indication
Insulin detemir is indicated to improve glycemic control in adults and children with diabetes mellitus.
- Associated Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Associated Therapies
- -
Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine in Patients With Type 1 Diabetes
- Conditions
- First Posted Date
- 2006-04-07
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 325
- Registration Number
- NCT00312104
- Locations
- 🇿🇦
Novo Nordisk Investigational Site, Cape Town, Western Cape, South Africa
Comparison of Efficacy and Safety of Insulin Detemir and NPH Insulin in Children and Adolescents With Type 1 Diabetes
- Conditions
- First Posted Date
- 2006-04-07
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 347
- Registration Number
- NCT00312156
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Stirling, United Kingdom
Comparison of Insulin Detemir or Insulin Glargine as Add on to Oral Antidiabetic Drugs in Type 2 Diabetes
- Conditions
- First Posted Date
- 2006-01-30
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 583
- Registration Number
- NCT00283751
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Swansea, United Kingdom
Efficacy and Safety of a Fixed or a Flexible Supplementary Insulin Therapy in Type 2 Diabetes
- Conditions
- First Posted Date
- 2006-01-10
- Last Posted Date
- 2014-11-21
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 373
- Registration Number
- NCT00274274
Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes
- Conditions
- First Posted Date
- 2005-12-13
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 5652
- Registration Number
- NCT00264901
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Plainsboro, New Jersey, United States
Comparison of Insulin Detemir and Insulin Semilente®MC in Type 1 Diabetes
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 71
- Registration Number
- NCT00184639
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Hannover, Germany
Comparison of Insulin Detemir With NPH Insulin in Type 1 Diabetes
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 501
- Registration Number
- NCT00184665
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Istanbul, Turkey
Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 708
- Registration Number
- NCT00184600
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Wirral, Merseyside, United Kingdom
Hospital In-Patient Insulin Study
- Conditions
- First Posted Date
- 2005-08-25
- Last Posted Date
- 2007-05-01
- Lead Sponsor
- The Royal Bournemouth Hospital
- Target Recruit Count
- 41
- Registration Number
- NCT00135070
- Locations
- 🇬🇧
The Royal Bournemouth Hospital, Bournemouth, Dorset, United Kingdom
Comparison of Insulin Detemir Given Once or Twice Daily in Type 1 Diabetes
- Conditions
- First Posted Date
- 2005-07-08
- Last Posted Date
- 2017-06-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 520
- Registration Number
- NCT00117780
- Locations
- 🇱🇺
Novo Nordisk Investigational Site, Luxembourg, Luxembourg
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.